(Reuters) -Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi (NASDAQ:SNY) and Britain's...
By Geoffrey Smith Investing.com -- U.S. stock markets opened modestly higher on Tuesday, but another sign of the housing market weakening took much of the energy out of an...
Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Monday after renewed COVID-19 concerns.The new Delta variant has been spreading and is a major concern with it recently becoming...
Just when investors started to think that COVID-19 headlines no longer make a big impact on equities, news related to the spread of the Delta variant of the virus hit the market...
Regular readers of this column will note that we emphasize long-term investing in solid companies or exchange-traded funds (ETFs) that provide access to robust shares. For most...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Buy | Strong Buy |
| Technical Indicators | Sell | Strong Buy | Strong Sell | Buy | Strong Buy |
| Summary | Sell | Buy | Neutral | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 94.55 | 97.17 | 94.19 | -1.02 | -1.07% | 13.22M | ||||
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | ||||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | ||||
| 2.82 | 2.962 | 2.76 | -0.190 | -6.31% | 1.51M | ||||
| 94.33 | 95.19 | 92.59 | +0.48 | +0.51% | 1.85M | ||||
| 7.00 | 7.10 | 6.39 | 0.00 | 0.00% | 13.60K | ||||
| 141.93 | 142.91 | 139.26 | +1.91 | +1.36% | 122.06K | ||||
| 2,756.30 | 2,776.20 | 2,694.00 | +89.8 | +3.37% | 1.32M | ||||
| 60.97 | 62.83 | 59.21 | +1.06 | +1.77% | 1.04M | ||||
| 30.36 | 30.39 | 29.83 | +0.52 | +1.74% | 177.08K | ||||
| 9.78 | 9.78 | 9.77 | +0.010 | +0.10% | 6.09K | ||||
| 445.66 | 447.21 | 443.00 | +3.65 | +0.83% | 178.64K | ||||
| 187.76 | 188.48 | 185.67 | +2.42 | +1.31% | 735.42K | ||||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | ||||
| 8.05 | 8.44 | 7.97 | -0.57 | -6.61% | 28.13M |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
